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Summary 
CD2-mediated T lymphocyte activation requires surface expression of CD3-Ti, the T cell receptor 
(TCR) for antigen major histocompatibility complex protein. Given the importance of CD3~" 
in TCR signaling, we have directly examined the ability of the CD3~" cytoplasmic domain to 
couple CD2 to intracellular signal transduction pathways. A cDNA encoding a chimeric protein 
consisting of the human CD3~" cytoplasmic domain (amino acid residues 31-142)  fused to the 
CDSoL extracellular and transmembrane domains (amino acid residues 1-187)  was transfected 
into a CD2+CD3-CD8 -  variant of the human T  cell line Jurkat. The resulting transfectants 
expressed the CD8c~/CD3~" chimeric receptor at the cell surface in the absence of other TCR 
subunits. Stimulation of these transfectants with anti-T112  +  anti-T113 monoclonal antibodies 
(mAbs) initiated both a prompt cytosolic free calcium ([Ca2+]i) rise and protein tyrosine kinase 
activation.  Stimulation  with  either  intact  anti-T112  +  anti-T113 mAbs  or  purified  F(ab')2 
fragments resulted in interleukin 2 (Ib2) secretion. In contrast, control cell lines transfected with 
a cDNA encoding wild-type CDSol, and thus lacking surface expression of the CD3~'cytoplasmic 
domain, failed to show any [Ca2+]i rise, protein tyrosine kinase activation, or IL-2 secretion after 
identical stimulation. These data directly establish the CD3~" cytoplasmic domain as a necessary 
and sufficient component of the CD3-Ti complex involved in T lymphocyte activation through 
CD2.  Moreover, they show that CD2  signaling can function in the absence of Fc receptors. 
T  lymphocytes can be activated via the TCR (CD3-Ti) 
or by triggering through a number of other surface struc- 
tures, including CD2 in humans and Thy-1 in mice (1, 2). 
The same second messenger pathways are activated by stim- 
ulation via anti-CD2 mAbs or anti-TCR mAbs (3-6). In ad- 
dition, CD2-mediated T lymphocyte activation requires the 
presence of CD3-Ti at the cell surface (7-9). Both the TCR 
dependence of CD2 triggering and the similarities in activa- 
tion events triggered through CD2 or TCR imply a func- 
tional interaction between CD2 and the CD3-Ti complex. 
However, the role of the CD3-Ti subunits in coupling CD2 
to signal transduction mechanisms is unknown (10). A sub- 
stantial body of evidence has documented a central role for 
CD3~'in TCR-mediated triggering (11, 12). More recent work 
has shown that a CD3~" chimeric protein is sufficient by it- 
self to trigger early and late T cell activation events (13-15). 
We have employed a similar strategy to directly investigate 
the role of CD3~" in mediating CD2 signaling.  Here we show 
that  expression of the cytoplasmic domain of CD3~" as a 
CD8c~/CD3~" chimera at the cell surface in the absence of 
other TCR or FcR components is both necessary and sufficient 
to allow CD2-mediated T  cell activation. 
Materials and Methods 
Cell Lines.  J77 is a CD2+CD3+Ti+CD8-CD16  - derivative  of 
the leukemic human T cell line Jurkat. 31-13 is a CD2§  - 
mutant of J77 lacking a functional TiE subunit (8). These lines 
were maintained at 37~  in culture medium (RPMI 1640 +  10% 
FCS, 1 mM sodium pyruvate, 2 mM t-glutamine, 50 U/ml penicil- 
lin-streptomycin) under 5% CO2. WT-6, derived by transfection 
of 31-13 with J77 T'~ cDNA, thereby restoring surface CD3+Ti + 
expression (8), was maintained in culture medium supplemented 
with 0.5 mg/ml G418 (Gibco/BRL,  Gaithersburg, MD). 
Antibodies.  The specificities, designations, and isotypes of the 
murine mAbs used in this study are as follows: anti-CD2:  anti- 
Tl11, 3T4-SB5, IgG2a; anti-T112: 1Old2-4C1, IgG2; anti-T11~: 
1Mono2A6, IgG3; anti-CD3: 2Ad2A2, IgM, or RW28C8, IgG1; 
anti-CD4:  19ThySD7, IgG2; anti-CD8:  21Thy2D3, IgG1. N23 
is a rabbit anti-human CD3~"  antiserum raised against the human 
CD3~" COOH-terminal peptide CDTYDALHMQALPPR  con- 
jugated to BSA using sulfo-MBS (Pierce Chemical Co., Rockford, 
IL) according to the supplier's directions and shown to immuno- 
precipitate and Western blot human CD3~'. 4G10 antiphosphotyro- 
sine murine mAb was kindly provided by Dr. Brian Druker (DFCI, 
Boston, MA) (15). Purified anti-T112 and anti-T113 F(ab')2 frag- 
ments were prepared as described (16). 
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coding region of human CDS~ was amplified from clone pL2-M 
(17) (kindly provided  by Dr. Jane Parries, Stanford  University,  Stan- 
ford, CA) using oligonudeotides containing a 5' BgllI recognition 
sequence (CDScz 5' sense oligonudeotide: nudeotides 88-108 of 
reference 17, 5'GCGAAGATCTTTGGCCATGGCCTTACCAGT- 
GACCGCC3';  CDS~ 3' antisense oligonucleotide: nucleotides 
773-795 of reference 17, 5'CGCGAGATCTTTAGACGTATCTCG- 
CCGAAA~3'). After gel purification  and digestion with BgllI, 
the fragment was subcloned into the BamHI site of the expression 
vector pPink2 (18) creating a construct termed pCD8~/Pink2 for 
use in transfection (see below). Similarly, a chimeric cDNA en- 
coding  the  NH2-terminal 187  amino acids of CD8c~ fused to 
amino acid residues 31-142 of human CD3~"  clone was generated 
by annealing overlapping PCR  fragments encompassing these 
regions amplified from CD8~ (clone pb2M)  and CD3~" (done 
pGEM3z~" (19), kindly provided by Drs.  Allan Weissman and 
Richard Klausner, National Institutes of Health, Bethesda, MD), 
respectively (CDSc~ chimera 5' sense oligonucleotide identical to 
CDS~ 5' sense oligonucleotide listed above; CDSc~/CD3~'overlap 
antisense oligonucleotide: 5'GCGCTCCTGCTGAACTTCACT- 
CTGTGGTTGCAGTAAAGGG3'; CDSc~/CD3~" overlap sense 
oligonudeotide:  5  'GGTTATCACCCTTTACTGCAACCACAG- 
AGTGAAGTTCAGCAGG3'; CD3~'3' antisense oligonudeotide 
nudeotides 545-566 from reference 19: 5'CGCGAGATCTTTAGC- 
GAGG~AGGC~CTGC3'). The two overlapping PCK frag- 
ments were annealed and filled in using the Klenow fragment of 
DNA polymerase,  and 10% of  the products from this reaction were 
subjected to PCK amplification with CD8c~ 5' sense and CD3~'3' 
antisense oligonudeotides to yield the chimeric  CDSol/CD3 ~"  PCR 
fragment. After gel purification and BgllI digestion, the fragment 
was subcloned into the BamHI site of pPink2 resulting in a con- 
struct  termed pCD8c~/CD3~'/Pink2.  Identity of the  resulting 
plasmids was verified  by restriction enzyme analysis  and DNA se- 
quencing. 
Transfections and Selection.  pCDS~/CD3~'/Pink2  and pCDSa/ 
Pink2 were each transfected  into 31-13 cells  by electroporation  using 
a cell porator system (Gibco/BRL) with a capacitance set at 330 
#F. Transfectants  were selected in culture medium supplemented 
with 1.0 mg/ml G418. Resistant clones were further selected for 
CD8 surface expression by indirect immunofluorescence analysis 
(16). Positive  clones were maintained in culture medium containing 
0.5 mg/ml G418. 
Cell Su~ce Labelin,~ Immunoprecipitation, and Electroyhoresis.  lO  s 
cells were washed four times in ice-cold PBS (0.9% NaC1, 1 mM 
KC1, 15 mM NaPO4, pH 7.5), resuspended in 0.5 ml PBS, and 
labeled with 2 mCi Na12SI (NEN/Dupont,  Wilmington, DE) 
using the lactoperoxidase  method. After washing three times with 
cold TBS (25 mM Tris, pH 7.5, 0.9% NaC1, 1 mM KC1), cells 
were lysed  in 1% digitonin lysis  buffer as described  (20). Postnuclear 
supernatant  from  2  x  107  cells was  immunoprecipitated by 
rotating  overnight  at  4~  with  60  /~1  mAb-coupled protein 
A-Sepharose beads (~2-4 mg mAb/ml beads) in the case of CD2, 
CD3,  CD4,  and CDS,  and 5 #1 antiserum and 60/~1 protein 
A-Sepharose beads in the case of anti-CD3~"  or nonimmune rabbit 
serum. Antigen-antibody-bead  complexes  were washed, solubilized, 
and analyzed  by SDS-PAGE as described (20). Western blots were 
performed as described (20), except that alkaline  phosphatase-con- 
jugated goat anti-rabbit  IgG (Bio-Rad Laboratories, Richmond, 
CA) was used as the second step. Bands were visualized after de- 
veloping the blots according to the supplier's directions. 
Protein Tyrosine  Kinase Activation.  Aliquots of 107 cells, washed 
in HBSS (Gibco/BRL) at 25~  were resuspended  in 0.5 ml HBSS 
at 37~  and stimulated with a 1:100 dilution of the indicated anti- 
body at 37~  Stimulation  was quenched  at various  times by adding 
0.5 ml ice-cold 2x  lysis buffer (2% Triton X-100 in 50 mM Tris, 
pH 7.5, 20 mM EDTA, 10 mM NaF, 2 mM Na3VO4, 10 mM 
Na4P207) for 25 rain followed by centrifugation. Baseline (time 
0) samples were obtained by adding stimulating antibody after 
quenching cell suspensions with 2x lysis  buffer. 50 #1 (10%) of the 
resulting  postnudear lysates  was solubilized  in 2 x reducing  Laemmli 
sample buffer and analyzed  by 7.5-17.5% gradient SDS-PAGE and 
Western blotting with 4G10 antiphosphotyrosine  mAb as described 
above. The remaining lysate  material was immunoprecipitated  with 
anti-CD3~', resolved by 7.5-17.5% gradient SDS-PAGE and ana- 
lyzed by Western blotting with 4G10 as described (20), using bi- 
otinylated goat anti-mouse IgG (Sigma Chemical Co., St. Louis, 
MO) followed by streptavidin plus biotinylated alkaline phospha- 
tase as a second step (Bio-Rad Laboratories). 
Cytosolic Free Cakium ([Ca2+]i  9 Measurement.  After overnight 
incubation in G418-free  culture medium, aliquots containing 2 x 
106 cells were resuspended in 0.5 ml culture medium containing 
2 #g/ml of the acetoxymethyl ester of indo-1 (Molecular Probes, 
Eugene, OR) for 45 min at 37~  Subsequently,  cells  were pelleted 
and resuspended in 2 ml culture medium. Fluorescence measure- 
ments were made using a fluorimeter (SFM25; Kontron, Zurich, 
Switzerland) with excitation and emission wavelengths  of 350 and 
405 nm, respectively. Baseline fluorescence was monitored for 3 
min, after which a 1:200 dilution of  antibody was added  and fluores- 
cence monitored for 15 min. The cells were kept in suspension by 
constant stirring. At the end of each analysis,  maximal fluorescence 
was determined by adding Triton X-100 to 0.05% and minimal 
fluorescence determined  after  addition  of EGTA to  2.5  raM. 
[Ca2+]i  was  calculated as described (21). 
Determination oflL2 Production.  los cells were plated in 96-well 
round-bottomed plates (final volume, 0.2 ml) and stimulated at 
37~  for 24 h in the presence of 5 ng/ml PMA with either anti- 
CD3 (2Ad2A2), anti-T112 (1Old2-4C1) plus anti-Tll~ (1Mono2A6), 
anti-CD8 (21Thy2D3), or calcium ionophore (A23187 at 1/~g/ml 
final concentration; Sigma Chemical Co.). All mAbs were used 
either as ascites at saturating  concentration  (1:200 final)  or in purified 
form at 10/xg/ml final concentration. Serial dilutions of culture 
supernatants were then tested for their capacity to support prolifer- 
ation of 104 CTLb20 cells as described (22). 
Results and Discussion 
Transfection  of  the  Jurkat  CD3-  mutant  line  31-13 
resulted in 12 independently derived surface CD8-expressing 
clones for each cDNA denoted 31-13.c~ for plasmid pCDSc~/ 
Pink2 or 31-13.ol~" for pCD8o~/CD3~'/Pink2, respectively. 
Flow cytometric analysis of representative clones for each con- 
struct are shown in Fig.  1. Whereas J77, 31-13, and WT-6 
(a 31-13 transfectant in which CD3-Ti surface expression has 
been restored after transfection of a wild-type TiE cDNA 
[8]) express no detectable CDS, 31-13 transfectants containing 
either  full-length  CD8ol  cDNA  (31-13.o~2) or  chimeric 
CD8c~/CD3~"  cDNA  (31-13.c~p5,  31-13.o~'11)  expressed 
readily detectable CD8 at the surface. The expression level of 
CD8 was reproducibly greater in the native CDSc~-containing 
lines as compared with clones expressing CDSoe/CD3~" chi- 
1  Abbreviation used in this paper: [Ca2+]i,  cytosolic  free calcium. 
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Figure  1.  Surface  phenotype of Jurkat derivatives and transfectants. 
Immunofluorescence  analysis  of  Jurkat derivatives  J77, 31-13 (CD3-/Ti-), 
WT-6 (CD3+/Ti+), 31-13.c~2  (CD3-/Ti-,CD8c~+), 31-13.a~ (CD3- / 
Ti- ,CDSc~/CD3~  "+), and 31-13~1 (CD3-/Ti- ,CD8~/CD3~  "+ ). His- 
tograms display reactivity with the indicated murine anti-human mAb 
(thick  line)  as compared with second step alone (thin  line). 
meric protein. Neither 31-13 nor any of the transfectant clones 
containing CD8ot or chimeric CD8ot/CD3~" expressed sur- 
face CD3, while all lines expressed comparable levels of sur- 
face CD2  (Fig.  1). 
To characterize the CD8ot and CD8cc/CD3~" proteins ex- 
pressed on the surface of the above transfectants,  cells were 
immunoprecipitated with antibodies to CD8, CD3~', CD2, 
CD3e,  and,  as a control,  CD4 after surface iodination  and 
digitonin lysis. Nonreducing SDS-PAGE analysis of anti-CD2 
immunoprecipitates  revealed the characteristic  55-kD band 
in both CD8ot- and CD8ot/CD3~'-expressing clones (31-13.a2 
and 31-13.ot~;  Fig. 2 A, lanes 1 and 4).  In contrast,  CD3 
and CD4 (as a negative control) were undetectable on these 
cell lines (Fig. 2 A, lanes 2, 3, 5, and 6). Immunoprecipita- 
tion of done 31-13.c~2 with anti-CD8 revealed a single band 
of 24 kD under reducing conditions (Fig. 2 B, lane 1). This 
agrees with the predicted size for unglycosylated CD8c~ (17) 
and suggests that, in accordance with prior observations (13), 
Jurkat and its variants may be deficient in their ability to per- 
form  certain  aspects  of posttranslational  modification  of 
CDS~. Under nonreducing conditions, higher molecular mass 
multimers  were observed, consistent with  the known  pat- 
Figure  2.  Biochemical  characterization of 31-13 transfectants. Surface 
iodinated cells were lysed  in digitonin containing lysis buffer  and immu- 
noprecipitated with the indicated antibody-conjugated  beads (anti-CD2, 
anti-CD3, and anti-CD8) or antibody-coated  protein A-Sepharose (anti- 
CD4, rabbit anti-CD3~. Immunoprecipitates  were dissolved  in Laemmli 
SDS sample  buffer, and analyzed by SDS-PAGE (12.5% acrylamide) and 
subsequent autoradiography. Each lane contains material from ,~107 cells. 
(.4) Analysis  of  CD8c~  (31-13.ot2)-  and CD8c~/CD3~"  01-13.cxS"6)-expressing 
transfectants under nonreducing  conditions  after  immuuoprecipitatiou  with 
anti-CD2, anti-CD3, and anti-CD4. (B) Analysis of CD8ex (31-13.ot2) 
and CDSc~/CD3~"  (31-13.a~11) transfectants under reducing and non- 
reducing conditions after immunoprecipitation with anti-CD8 or rabbit 
anti-CD3~"  (antiserum N23)  as indicated. (C) Western  blot analysis  of CDSc~ 
(31-13.c~4)-  and CD8c~/CD3g"  (31-13.ot~'4)-expressing  transfectants. Anti- 
CD8 immunoprecipitates of 31-13.~4 and 31-13.ot~'4  were transferred to 
nitrocellulose after SDS-PAGE  and probed  with the rabbit anti-CD3~"  an- 
tiserum N23 as described in Materials and Methods. 
tern for CD8a (31-13.a2;  Fig. 2 B, lane 3). A  species of 33 
kD, consistent with the size predicted for an unglycosylated 
CDSo~/CD3~" chimeric protein,  was observed in anti-CD8 
immunoprecipitates of CD8cffCD3~" transfectants as shown 
for clone 31-13.otD1  under reducing  conditions  (Fig.  2 B, 
lane 5). Parallel  analysis of immunoprecipitates  of this clone 
with rabbit anti-CD3~" revealed a 33-kD band with similar 
mobility to the band immunoprecipitated  with anti-CDSa 
(Fig.  2 B,  lane 6).  Immunoprecipitation  analysis  of clones 
31-13.ol~'4 and 31-13.otp5  yielded results in agreement with 
those for 31-13.a~11  (data not shown).  The identity of the 
33-kD  species as  the  chimeric  CDSc~/CD3~" protein  was 
confirmed  by  Western  blot  analysis  of  anti-CDSc~  im- 
munoprecipitates of 31-13.o~'4 with rabbit anti-CD3~" (Fig. 
2 C, lane 2). Under nonreducing conditions,  anti-CD8 and 
rabbit  anti-CD3~"  immunoprecipitates  of transfectants  ex- 
pressing CD8odCD3~" revealed  a major species of "~ 100 kD 
(Fig.  2 B,  lanes  7 and 8),  which would correspond  to the 
size predicted for a homotrimer. This band was also apparent 
in anti-CD8  immunoprecipitates  subjected to nonreducing 
SDS-PAGE and Western blot analysis with rabbit anti-CD3~" 
(31-13.ot~'4; Fig. 2 C, lane 4). Note that the '~60-kD mate- 
rial  seen under nonreducing  conditions is nonspecific,  as is 
evident  in all  nonreducing  sample lanes  (Fig.  2  C,  lanes  1 
and 2; and data not shown). Given the absence of other specific 
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Figure 3.  Calcium mobiliza- 
tion after receptor crosslinking 
in Jurkat  derivatives and trans- 
fectants. Cell lines loaded with 
Indo-1 were stimulated (arrowhead) 
with 1:200 dilutions  ofascites  con- 
taining  anti-CD8  (21Thy2D3), 
anti-CD2  (anti-T112  [101d2- 
4C1] + anti-T113  [1Mono2A6]), 
or anti-CD3 (2Ad2A2) as indi- 
cated. Fluorescence emission at 
405 nm was monitored continu- 
ously for >3 min before stimula- 
tion and for >12 min afterwards. 
ICa+2]i  was  determined as  de- 
scribed in Materials and Methods. 
These results are representative 
of seven independently derived 
CD8odCD3~'chimeras  expressing 
31-13 transfectants and seven in- 
dependently derived fuU-length 
CDS~-expressing  31-13  trans- 
fectants. 
bands  on  one-dimensional  analysis with  anti-CD3~" under 
reducing conditions (Fig. 2 B; and data not shown), we con- 
clude that the higher molecular mass species seen under non- 
reducing  conditions  represent  homo-multimers. 
The ability of the chimeric protein to participate in trans- 
ducing T  cell activation signals was assessed by monitoring 
[Ca + 2]i mobilization as a function of surface receptor cross- 
linking. As shown for WT-6 (CD2+CD3+CD8-),  addition 
of an anti-CD3 antibody or a mitogenic combination of anti- 
CD2 antibodies results in a prompt rise in intracellular cal- 
cium (Fig. 3, B and C). As expected, anti-CD8 did not elicit 
a  calcium  rise in  these cells  (Fig.  3  A),  even when  rabbit 
anti-mouse Ig was added as a second step (data not shown). 
Moreover, stimulation of the CD2+CD3 -  parental line 31- 
13 with anti-CD2,  CD3,  or CD8 mAbs failed to mobilize 
calcium (Fig. 3, D, E, and F). No calcium rise was observed 
in cell lines expressing the full-length CD8ot protein after 
stimulation with anti-CD8  (Fig.  3,  G  and J).  In contrast, 
after anti-CD8 treatment of CD8o~/CD3~'-expressing clones, 
a prompt rise in intracellular calcium was detectable within 
3 rain (Fig. 3, M  and P). These results demonstrate the im- 
portance of the CD3~" subunit  in mediating  signaling  and 
are entirely consistent  with previous observations  (13-15). 
We next determined whether the CD8ot/CD3~" structure 
could functionally substitute for the entire CD3-Ti complex 
and allow T cell activation through CD2. As shown in Fig. 
3,  CD2 crosslinking with anti-T112 plus anti-T113 resulted 
in a prompt increase in [Ca  2+ ]i in the case of CD8ot/CD3~" 
chimera-containing  clones  (shown  for  31-13.ot~  and  31- 
13.c~11; Fig. 3, N  and Q), similar to that seen in WT-6 (B). 
In contrast, no calcium rise was detected in transfectants ex- 
pressing full-length CD8ot (31-13.c~2;  Fig. 3, H  and K). The 
lack of detectable calcium mobilization in response to anti- 
CD3 in 31-13 and all CD8ot and CDScffCD3g" transfectants 
as well as the CD3-  parental line (Fig. 3, F, I, L,  O,  and 
R) is consistent with the absence of surface CD3. Crosslinking 
with anti-CD4 failed to elicit a detectable calcium rise in any 
Table  1.  IL-2 Production by CD8ot/CD3~" Chimera-expressing Cell Lines 
IL-2 production 
r(ab')2 
Exp.  Cells  Media  Anti-CD3  Anti-CD8  Anti-T112§  Ca ionophore  (anti-T112+3) 
U/mt 
1  WT-6  <2  32  <2  512  256 
31-13  <2  <2  <2  <2  128 
31-13.c~6  <2  <2  32  32  128 
31-13.a~1  <2  <2  64  64  128 
31-13.~2  2  <2  2  2  256 
2  WT-6  <2  256  128 
31-13.c~  2  64  128 
31-13.a2  2  2  64 
128 
32 
<2 
Cells were incubated for 24 h with various stimuli in the presence of 5 ng/ml PMA (final concentration). In Exp. 1, all antibodies were used as 
ascites at 1:200 final concentration. For Exp. 2, all antibodies and F(ab')2 fragments were used at 10/~g/ml  final concentration. Supernatants were 
harvested and tested in duplicate in serial dilution for their capacity to support the growth of the IL-2-dependent murine T cell line CTLL20. Results 
are expressed in arbitrary U/ml of IL-2 secreted. The last dilution able to maintain the viability of 10,000 CTLL-20 cells was defined as containing 
1 arbitrary U/ml. Titration experiments performed in parallel with rlL-2 (Biogen, Cambridge, MA) revealed that 1 arbitrary U is equivalent to 
'x'1.2 U of rlL-2. The data shown are representative of three (Exp. 1) or two (Exp. 2) independent experiments. 
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31-13 transfectant by anti-CD2 or anti-CD8. Aliquots of 107 31-13.ot~6 
cells were stimulated with the indicated antibodies at 1:100 dilution for 
various times in minutes as shown.  10% of the postnuclear lysate from 
each sample was directly subjected to SDS-PAGE (7.5-17.5% acrylamide), 
while the remaining 90% was immunoprecipitated with rabbit anti-CD3~" 
antiserum N23, and then subjected to SDS-PAGE (7.5-17.5% acrylamide). 
After  transfer  to  nitrocellulose,  all  samples  were  probed  with  an- 
tiphosphotyrosine mAb 4G10 and developed as described in Materials and 
Methods.  (a) Tyrosine phosphorylation of proteins in total posmuclear 
lysates of 31-13.c~ cells stimulated with anti-CDS, anti-CD3, or anti- 
CD2 (antiT112  +  anti-T113) as a function of time. Bands  appearing as 
a result of stimulation are denoted pp170, pp110, ppl00, pp72, and pp34. 
IgH and IgL denote antibody heavy chain and light chain, respectively. 
(b) Tyrosine phosphorylation of CDS,v/CD3~" chimeric protein from anti- 
CD3~" immunoprecipitates of 31-13.ot~  cells  stimulated as in a.  The 
CDSa/CD3~" chimera is denoted pp34. 
of the Jurkat derivatives used herein, confirming the specific 
nature of activation via CD3~" (data  not shown). 
We further investigated the ability of the chimeric CD8od 
CD3~" to reconstitute CD2-stimulated II~2 production in the 
absence  of surface  CD3/Ti.  As  expected,  stimulation of 
CD8ol/CD3g" chimera-expressing cells with anti-CD8 resulted 
in Ib2 production (Table 1, Exp. 1). The magnitude of the 
IL-2 response from CDSot/CD3~" chimera-expressing lines 
after CD8 triggering was consistently found to be quantita- 
tively similar to the levels of Ib2 production from CD3/Ti + 
line WT-6 stimulated with anti-CD3. More importantly, stim- 
ulation of CDSot/CD3~" chimera-expressing TCR- clones, 
of which 31-13.otp5 and 31-13.a~'11 are representative,  with 
anti-T112 plus anti-T113 for 24 h, resulted in significant levels 
of II.-2 production. As previously reported, stimulation of 
WT-6 through CD2 resulted in an II:2 response exceeding 
that of anti-CD3 stimulation by an order of magnitude (8). 
Interestingly, CD2 stimulation of CD8~/CD3~" chimera- 
expressing TCR-  clones produced levels of IL-2 comparable 
in magnitude with CD8 triggering of these cells, but clearly 
less than the Ib2 response of CD2-stimulated WT-6 (Table 
1, Exp.  1). CD2 stimulation of WT6 or 31-13.o~p5 using 
purified anti-Tll2 plus anti-Tll3 F(ab')2 fragments resulted in 
levels of II.-2 production comparable with levels seen using 
intact IgG (Table 1, Exp.  2).  As expected, the CD3-  line 
31-13 and transfectants expressing only full-length CDSot, 
of which 31-13.c~2 is representative, failed to produce detect- 
able amounts of IL-2 to any of the above stimuli. Neverthe- 
less, since a combination of PMA and calcium ionophore in- 
duced IL-2 production from each cell line tested, lack of I~2 
production from 31-13 or 31-13.ot2 is not a consequence of 
an intrinsic defect in IL-2 gene induction (Table 1, Exp.  1). 
The ability of purified anti-T112 plus anti-T113 F(ab')2 frag- 
ments to elicit  IL-2 production in the CD8ot/CD3~" chi- 
mera-expressing clone excludes a role for Fc receptors in medi- 
ating this effect. 
To examine the role of the CDSot/CD3~'chimera in CD2- 
stimulated protein tyrosine kinase activation, we compared 
the patterns of tyrosine phosphorylated proteins after stimu- 
lation through CD2 or the chimeric receptor.  Western blot 
analysis  of 31-13.c~p5 total  cellular  lysates  using  an  an- 
tiphosphotyrosine  mAb disclosed a number of substrates that 
became tyrosine phosphorylated as a result of either anti-CD2 
or anti-CD8 stimulation when compared with the zero time 
points or stimulation with anti-CD3 (Fig. 4 a, lanes I-4 and 
5-13). Interestingly, several substrates  were phosphorylated 
in response to either anti-CD2 or anti-CD8 (denoted pp170, 
ppl00, pp72), whereas at least one substrate (pp110) was evi- 
dent only after CD2 stimulation (Figure 4a, compare lanes 
4,  7,  10,  and I3 with lanes 2, 5, 8,  and I1).  In addition, 
the appearance of new bands in the 34-kD range suggested 
that the chimeric receptor was tyrosine phosphorylated as 
a result of either CD8 or CD2 stimulation (Fig. 4 A, lanes 
5,  7,  8,  10,  11,  and 13). To confirm this, anti-CD3~" im- 
munoprecipitates of part of the material analyzed in Fig. 4 
a were subjected to SDS-PAGE and Western blotting using 
antiphosphotyrosine  mAb. This analysis dearly demonstrates 
that the chimeric receptor (denoted pp34) is phosphorylated 
as a result of either anti-CD8  stimulation (Fig.  4  b, lanes 
5, 8, and I1) or anti-CD2 stimulation (Fig. 4 b, lanes 7, I0, 
143  Howard et al. and  13).  It  should  be  noted  that  the  time  to  maximal 
CD8c~/CD3g" phosphorylation was much shorter for CD8 
stimulation ('~1 min) than for CD2-mediated activation ("~15 
min) (Fig. 4b, lanes 4 and 13; and data not shown). The basis 
for this kinetic difference remains to be determined.  As ex- 
pected,  stimulation  of cell line 31.12.ot2  with  CD2,  CD3 
or CD8 failed to yield any specific tyrosine phosphorylated 
protein bands in Western blot analysis of either total cellular 
lysates or anti-CD3~" immunoprecipitates (data not shown). 
That the cytoplasmic domain of CD3~'can function in lieu 
of  the  TCR  complex  (Tio~-~/CD33,/~e[~'-~" or  ~'-~/]) in 
facilitating  T cell activation  through CD2 suggests that CD3~" 
is a critical TCR component in T  cells necessary for coup- 
ling CD2 to cytoplasmic second messenger pathways. This 
conclusion is particularly noteworthy given that in NK cells, 
in contrast to T  cells,  CD2 signaling activates second mes- 
senger pathways in the absence of TCR. (23). Interestingly, 
NK cells express cell surface CD3~" as a component of a mo- 
lecular complex with the low affinity IgG Fc receptor CD16 
(Fc3'tLIII)  (24). This observation suggests that in NK cells 
CD3~" may also play a central  role in CD2-mediated  trig- 
gering. Consistent with this notion, we have recently shown 
that  transfection  of a  CD3-  CD2 § Jurkat  line  with  the 
transmembrane  form of CD16 results in surface expression 
of CD16 in association with endogenous CD3~" homodimers 
and restores CD2-mediated activation  (16). While these results 
further underscore the importance of CD3~'in mediating CD2 
signaling, we can not exclude a functional role for other com- 
ponents of the TCR (e.g., CD334~E  ) in this process. In fact, 
the  quantitative  difference  in  ILo2 production  by  CD2- 
stimulated CD8ot/CD3~" chimera-expressing  lines as com- 
pared with TCR-expressing lines may reflect the participa- 
tion of other TCR components in the CD2 signaling pathway. 
Although  previous  work  has  documented  a  role  for  Fc 
receptors in anti-CD2 mAb-mediated signaling under some 
experimental conditions (25, 26), the present findings with 
the FcR-  cell line Jurkat  using purified F(ab')2  fragments 
show that CD2 triggering can function independently of FcR 
subunits. 
The biochemical bails of the functional dependence of CD2 
signaling on CD3~" is presently unknown.  It is dear, how- 
ever, that the cytoplasmic domains of both CD2 and CD3~" 
are required for this functional interaction  (16,  27), which 
implies that the relevant biochemical components are intra- 
cellular structures.  The fact that  T  cell activation  through 
the PI-linked surface structure Thy-1 has been shown to re- 
quire cell surface CD3~" (10) makes a direct physical associa- 
tion between this extraceUular structure and CD3~" unlikely. 
Similarly,  the interaction  between CD2 and CD3~',  if not 
direct,  may be indirect  and/or  transient  and involve as yet 
unidentified cellular constituents. The ability of a single chain 
chimeric receptor to link accessory molecules to second mes- 
senger pathways should further  facilitate molecular dissec- 
tion of biochemical components and interactions important 
in mediating T cell activation through CD2 and other acces- 
sory structures. 
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